Combining Chemotherapy Drugs for Advanced Solid Tumors
Author Information
Author(s): Chen X, Oza A M, Kusenda Z, Yi Q-L, Kochman D, Moore M J, Davis A J, Siu L L
Primary Institution: Princess Margaret Hospital, University Health Network
Hypothesis
A combination chemotherapy regimen consisting of irinotecan, cisplatin, and epirubicin (PIE regimen) would have synergistic activity against solid tumours.
Conclusion
The combination of irinotecan, cisplatin, and epirubicin showed promising antitumour activity in patients with advanced solid tumors.
Supporting Evidence
- 10 patients achieved a major objective response: one complete response and nine partial responses.
- 34 patients were evaluable for tumor response, with 13 patients having stable disease.
- The recommended phase II doses were determined to be irinotecan 110 mg/m², cisplatin 50 mg/m², and epirubicin 60 mg/m².
Takeaway
Doctors tested a mix of three cancer-fighting medicines to see if they work better together, and they found that they helped some patients get better.
Methodology
Patients with advanced solid tumors received a combination of irinotecan, cisplatin, and epirubicin every three weeks, with dose adjustments based on toxicity.
Potential Biases
Potential bias due to the single-institution study design and the specific patient population selected.
Limitations
The study was limited by its small sample size and the focus on safety rather than definitive efficacy.
Participant Demographics
The median age of participants was 53 years, with 51.4% male and 48.6% female.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 0–8.5% for complete response; 95% CI: 11.7–41.2% for partial responses.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website